5-(2-CHLOROETHYL)-5-ETHYL-2-(3-METHYL-2H-BENZO[B][1,4]OXAZIN-4(3H)-YL)THIAZOL-4(5H)-ONE


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	LCCXIQFBHLLBCZ-UHFFFAOYSA-N
Smiles	CCC1(CCCl)SC(=NC1=O)N2C(C)COc3ccccc23
InChI	InChI=1S/C16H19ClN2O2S/c1-3-16(8-9-17)14(20)18-15(22-16)19-11(2)10-21-13-7-5-4-6-12(13)19/h4-7,11H,3,8-10H2,1-2H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C16H19ClN2O2S
Molecular Weight	338.85
AlogP	3.97
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	4.0
Polar Surface Area	67.2
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	22.0

Assay Description	Organism	Bioactivity
Post-emergence phytotoxicity against Oryza sativa (rice) plants exposed to compound applied on surface of water 7 days after transplantation assessed as plant killing at 0.5 kg ai/ha measured 3 weeks after compound treatment under green house conditions	Oryza sativa	0.0 %
Post-emergence herbicidal activity against Echinochloa oryzicola assessed as weed killing at 0.5 kg ai/ha measured 30 days after compound treatment under green house conditions	Echinochloa oryzicola	60.0 %
Post-emergence herbicidal activity against Echinochloa oryzicola assessed as weed killing at 2 kg ai/ha measured 30 days after compound treatment under green house conditions	Echinochloa oryzicola	100.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2287197
PubChem	76316447

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).